126 related articles for article (PubMed ID: 21208199)
1. Elevated HSP27 levels during attacks in patients with multiple sclerosis.
Ce P; Erkizan O; Gedizlioglu M
Acta Neurol Scand; 2011 Nov; 124(5):317-20. PubMed ID: 21208199
[TBL] [Abstract][Full Text] [Related]
2. Elevated HSP27 levels during attacks in patients with multiple sclerosis.
Li HF; Zhang HL
Acta Neurol Scand; 2012 Aug; 126(2):e8-9. PubMed ID: 22758205
[No Abstract] [Full Text] [Related]
3. Cytokine profile, Foxp3 and nuclear factor-kB ligand levels in multiple sclerosis subtypes.
Alatab S; Maghbooli Z; Hossein-Nezhad A; Khosrofar M; Mokhtari F
Minerva Med; 2011 Dec; 102(6):461-8. PubMed ID: 22193377
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
[TBL] [Abstract][Full Text] [Related]
5. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
[TBL] [Abstract][Full Text] [Related]
6. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity.
Sternberg Z; Weinstock-Guttman B; Hojnacki D; Zamboni P; Zivadinov R; Chadha K; Lieberman A; Kazim L; Drake A; Rocco P; Grazioli E; Munschauer F
Mult Scler; 2008 Jul; 14(6):759-63. PubMed ID: 18505774
[TBL] [Abstract][Full Text] [Related]
7. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis.
Szmyrka-Kaczmarek M; Pokryszko-Dragan A; Pawlik B; Gruszka E; Korman L; Podemski R; Wiland P; Szechinski J
Lupus; 2012 Apr; 21(4):412-20. PubMed ID: 22074845
[TBL] [Abstract][Full Text] [Related]
8. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
[TBL] [Abstract][Full Text] [Related]
9. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
[TBL] [Abstract][Full Text] [Related]
10. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
Pulizzi A; Rovaris M; Judica E; Sormani MP; Martinelli V; Comi G; Filippi M
Arch Neurol; 2007 Aug; 64(8):1163-8. PubMed ID: 17698707
[TBL] [Abstract][Full Text] [Related]
11. Serum prolactin level in patients with multiple sclerosis: a case control study.
Harirchian MH; Sahraian MA; Shirani A
Med Sci Monit; 2006 Apr; 12(4):CR177-80. PubMed ID: 16572053
[TBL] [Abstract][Full Text] [Related]
12. Patients with multiple sclerosis have higher levels of serum ghrelin.
Berilgen MS; Bulut S; Ustundag B; Tekatas A; Ayar A
Neuro Endocrinol Lett; 2005 Dec; 26(6):819-22. PubMed ID: 16380704
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
[TBL] [Abstract][Full Text] [Related]
14. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
15. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.
Verbeek MM; Notting EA; Faas B; Claessens-Linskens R; Jongen PJ
Acta Neurol Scand; 2010 May; 121(5):309-14. PubMed ID: 19925532
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.
Thouvenot E; Orsini M; Daures JP; Camu W
Eur J Neurol; 2015 Mar; 22(3):564-9. PubMed ID: 25530281
[TBL] [Abstract][Full Text] [Related]
17. Serum prolactin level in patients with relapsing-remitting multiple sclerosis during relapse.
Moshirzadeh S; Ghareghozli K; Harandi AA; Pakdaman H
J Clin Neurosci; 2012 Apr; 19(4):622-3. PubMed ID: 22341909
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
19. The role of iron dysregulation in the pathogenesis of multiple sclerosis: an Egyptian study.
Abo-Krysha N; Rashed L
Mult Scler; 2008 Jun; 14(5):602-8. PubMed ID: 18408021
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
Khademi M; Kockum I; Andersson ML; Iacobaeus E; Brundin L; Sellebjerg F; Hillert J; Piehl F; Olsson T
Mult Scler; 2011 Mar; 17(3):335-43. PubMed ID: 21135023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
